{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T04:20:03Z","timestamp":1729052403003},"reference-count":0,"publisher":"African Journals Online (AJOL)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Afr H. Sci."],"abstract":"<jats:p>Introduction: Resistance to tyrosine kinase inhibitors (TKIs) is an obstacle facing CML patients in spite of the high cure rate. In this context, a study association between IGFBP (1, 2, 3) genes expression and their proteins in CML with the response to TKI has been implicated.\r\nPatients and methods: 115 newly diagnosed CML in chronic phase (CP) followed up over 12 months under TKI. 116 apparently healthy individuals were used as a control. RT-qPCR amplification was used for detecting IGFBPs genes expression, and ELISA technique was used for measuring serum IGFBPs.\r\nResults: IGFBP-1 and IGFBP-3 genes expression, as well as their serum levels, were significantly higher in CML patients, whereas IGFBP-2 gene expression was not. Interestingly, IGFBP-1 gene expression and IGFBP-1 serum levels were significantly higher in resistant patients compared to responder patients. However, the expression of IGFBP-2, 3 genes and their serum were insignificant.\r\nConclusion: IGFBP-1 gene expression and its serum were significantly correlated with resistance. It is currently recommended that IGF-receptor inhibitors be developed and utilized. We are hoping to optimize the cure rate for CML treated with TKIs.\r\nKeywords: IGFBP-1-3; Gene expression; CML; Imatinib; Nilotinib.<\/jats:p>","DOI":"10.4314\/ahs.v24i3.26","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T12:54:09Z","timestamp":1728996849000},"page":"216-229","source":"Crossref","is-referenced-by-count":0,"title":["The utility of Insulin Like Growth Factor Binding Proteins (IGFBPs-1, 2, 3)  with genes expression in resistance to Imatinib and Nilotinib in chronic  myeloid leukemia: a pilot study from Delta Egypt"],"prefix":"10.4314","volume":"24","author":[{"given":"Nadia","family":"El Menshawy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Sabry El-Ghonemy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaimaa","family":"El-Ashwah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Elkerdawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramy","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mostafa","family":"Abdelhakiem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maha","family":"Saif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"EL-Sebaie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2895","published-online":{"date-parts":[[2024,10,6]]},"container-title":["African Health Sciences"],"original-title":[],"link":[{"URL":"https:\/\/www.ajol.info\/index.php\/ahs\/article\/download\/280055\/264154","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajol.info\/index.php\/ahs\/article\/download\/280055\/264154","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T12:54:32Z","timestamp":1728996872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajol.info\/index.php\/ahs\/article\/view\/280055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,6]]},"references-count":0,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,10,6]]}},"URL":"https:\/\/doi.org\/10.4314\/ahs.v24i3.26","relation":{},"ISSN":["1729-0503","1680-6905"],"issn-type":[{"value":"1729-0503","type":"electronic"},{"value":"1680-6905","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,6]]}}}